Clinical Trials Logo

Parkinson's Disease clinical trials

View clinical trials related to Parkinson's Disease.

Filter by:

NCT ID: NCT01058291 Completed - Parkinson's Disease Clinical Trials

Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500

6500-004
Start date: January 2010
Phase: Phase 3
Study type: Interventional

This is a placebo-controlled double-blind crossover comparative study of KW-6500 in Parkinson's disease patients with motor response complications on levodopa therapy. The efficacy of KW-6500 is evaluated using the change of UPDRS part III score at double blind period after 12 weeks subcutaneous self-injections.

NCT ID: NCT01055379 Completed - Parkinson's Disease Clinical Trials

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

ACCORDO
Start date: March 2010
Phase: Phase 4
Study type: Interventional

The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.

NCT ID: NCT01052948 Completed - Parkinson's Disease Clinical Trials

The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events

Start date: January 2007
Phase: N/A
Study type: Observational

To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2. Diffuse Pleural/pulmonary thickening and pericardial and retroperitoneal fibrosis 3. Heart failure 4. Total, cardiac and respiratory mortality

NCT ID: NCT01052350 Active, not recruiting - Parkinson's Disease Clinical Trials

PET Imaging in Parkinson Disease Dementia

Start date: August 2006
Phase:
Study type: Observational

The purpose of this study is to use a brain imaging method called PIB PET to determine dementia subtypes in patients with Parkinson's disease. The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia.

NCT ID: NCT01049984 Completed - Parkinson's Disease Clinical Trials

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

ANDANTE
Start date: December 2009
Phase: Phase 4
Study type: Interventional

To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.

NCT ID: NCT01038310 Completed - Parkinson´s Disease Clinical Trials

Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease

Start date: January 2010
Phase:
Study type: Observational

The investigators aim to study whether the nuclear medicine method FP-CIT-SPECT (more details see below) allows to predict the further clinical course of Parkinson´s disease. Especially the investigators are interested in the motor and cognitive functions of the parkinsonian patients.

NCT ID: NCT01037686 Recruiting - Parkinson's Disease Clinical Trials

The Effect of Electrode Implantation for Deep Brain Stimulation (DBS) on Brain Function Using Single Photon Emission Computed Tomography (SPECT) With Technetium-99m-ethyl Cysteinatedimer (Tc-ECD)

Start date: February 2006
Phase: N/A
Study type: Interventional

The goal of this study is to explore the effect of subthalamic nucleus (STN)-DBS surgery and stimulation in PD (Parkinson's disease) patients on regional cerebral blood (CBF) flow during cognitive task performance or at rest.

NCT ID: NCT01036139 Completed - Parkinson's Disease Clinical Trials

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

HARPS1
Start date: December 2009
Phase: Phase 3
Study type: Interventional

To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649 in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's Disease.

NCT ID: NCT01032486 Completed - Parkinson's Disease Clinical Trials

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

PD
Start date: December 2009
Phase: Phase 4
Study type: Observational

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

NCT ID: NCT01023282 Completed - Parkinson's Disease Clinical Trials

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.